US drug approval and analgesia after rapid offset.
Reading Library · Anesthesia Epochs · 中文版
Watch the companion film
1996: Remifentanil — FDA Approval of Ultiva · Watch on YouTube
Historical anchor: 1996. Date details and source qualifications are explained below.
On 12 July 1996, the FDA issued Glaxo-Wellcome an approval letter for Ultiva. The original letter, the FDA drug register and a subsequent Federal Register notice agree on the date.[1, PDF pp.7,9;2, p.6550;3] This is a specific event: US drug approval for the product containing remifentanil. It does not date the molecule’s synthesis, its first administration in a research study or simultaneous marketing in other countries.

The approval letter described analgesia during induction and maintenance of general anesthesia, continuation into the immediate postoperative period under direct supervision by an anesthesia practitioner in a recovery or intensive care setting, and an analgesic component of monitored anesthesia care (MAC).[1, PDF p.7;2, p.6550] Analgesia is the operative distinction. The document placed the drug within an anesthetic and monitoring arrangement, without making it a sole solution to every requirement of anesthesia.
The meaning of short action becomes clearer when the metabolic route is specified. A later label preserved by the FDA in 2004 described remifentanil as a mu-opioid agonist with a labile ester linkage. Nonspecific esterases in blood and tissues hydrolyze that linkage, enabling rapid metabolism. The label distinguished this pathway from metabolism by plasma pseudocholinesterase.[4, printed pp.3,6] This later historical label provides the pharmacological explanation here; its full contents are not being attributed retrospectively to the original 1996 labeling.

The decline after administration stops is part of what makes the drug distinctive. The 2004 label described a duration of action that did not increase with prolonged administration and discussed the time for blood or effect-site concentrations to fall by half after an infusion.[4, printed pp.5–6] Such a context-sensitive decline is a different quantity from terminal elimination half-life or the time at which an individual patient awakens. A claim about rapid offset therefore needs to identify which process it describes.
Analgesia also dissipates rapidly. The 2004 label linked discontinuation of the infusion to establishing adequate postoperative analgesia and noted that other anesthetics could continue to affect respiratory recovery.[4, printed pp.14–15,26] Historically, this gave rapid offset two practical consequences: analgesic effects could be withdrawn promptly, while pain relief for the next stage had to be arranged. Rapid metabolism did not remove opioid-associated risks such as respiratory depression, apnea and muscle rigidity.[4, printed pp.4,14–15]

The authorized population subsequently changed. A supplemental approval letter dated 8 March 2004 extended analgesic use during maintenance of general anesthesia down to birth and added a description of a study in neonates and infants undergoing surgery for pyloric stenosis.[5, PDF pp.1,3] That extension belongs to a later regulatory step. Its age range should not be projected onto the 1996 approval or interpreted as an authorization for pediatric MAC.

A specific comparison connects this history with this site’s 1996: Diprifusor Puts a Pharmacokinetic Model Inside the Pump. A 2016 history of TCI described the original Diprifusor system as limited to branded propofol, whereas subsequent open TCI systems incorporated models for other drugs, including remifentanil.[6, pp.65–66] This links a drug’s time course with the devices and models used to administer drugs. It does not turn the 1996 FDA drug approval into authorization of those later devices or delivery modes.
The historical event therefore has two distinct documentary foundations. The approval letter establishes a date, jurisdiction and set of uses. Pharmacological records explain why stopping an infusion and preparing the next stage of analgesia belong together. Keeping the dates and scopes of those records visible gives a more precise account of both the short-acting drug and the arrangements around its use.[1–5]
Sources and reading limits
- FDA. NDA 20-630 original approval letter, 12 July 1996, addressed to Glaxo-Wellcome. Original review archive. Only the first 18 of 515 archive pages were viewed; final printed label not supplied in posted archive.
- FDA. Determination of Regulatory Review Period for Purposes of Patent Extension; ULTIVA. Federal Register. 12 February 1997;62:6549–6550. Official notice. Relevant notice read across both pages.
- FDA. Drugs@FDA, NDA 020630 approval history. Original approval 12 July 1996; supplement 5 approved 8 March 2004. Selected history fields read.
- FDA. Ultiva prescribing information, NDA 20-630/S-005, 2004. Historical label. Printed 3–7,14,15,26 read. Later historical labeling, not the original 1996 version or current prescribing guidance.
- FDA. Ultiva NDA 20-630/S-005 supplemental approval letter, 8 March 2004. Signed letter. All 3 pages read, including electronic signature.
- Struys MMRF, De Smet T, Glen JB, Vereecke HEM, Absalom AR, Schnider TW. The History of Target-Controlled Infusion. Anesth Analg. 2016;122:56–69. DOI 10.1213/ANE.0000000000001008. Published review in institutional repository. Printed 65–66 read for this article; later historical review, not original device authorization.
Thirty-three distinct pages were opened, including eight cover, divider or labeling-absence notice pages; the 515-page review archive was not read in full. The FDA letter, notice and register are records from the same regulatory system, not independent clinical validations. Egan and colleagues’ 1993 paper was available only as NLM metadata and abstract and supports no unique narrative claim here. Drug-name and population wording problems in the archive’s Study 214 were preserved; its results were not used. Images are modern editorial concepts in the original landscape format.
Continue exploring
Related reading connects shared questions and contexts; it does not by itself establish historical influence.
- 1974: Sufentanil's Developers Consider the Length of Surgery
- 1996: Diprifusor Puts a Pharmacokinetic Model Inside the Pump
The Source Room · About & Editorial Method
Sources and reading limits are stated above. Illustrations are labelled as original source images or AI-made. Historical accounts are educational; they are not current treatment instructions.